公开(公告)号：US12130288B2

公开(公告)日：2024-10-29

申请号：US16303345

申请日：2017-05-24

Applicant: Allegheny Singer Research Institute ,  Research Institute At Nationwide Children's Hospital

Inventor： Joseph M. Ahearn ,  Chau-Ching Liu ,  Susan M. Manzi ,  C. Yung Yu

IPC: C12Q1/68 ,  C12Q1/6883 ,  G01N33/564 ,  G16B20/10 ,  G16H10/40 ,  G16H15/00 ,  G16H50/30

CPC classification number: G01N33/564 ,  C12Q1/68 ,  C12Q1/6883 ,  G16B20/10 ,  G16H10/40 ,  G16H15/00 ,  G16H50/30 ,  C12Q2600/158 ,  G01N2800/104 ,  G01N2800/50

Abstract: Cell-bound complement activation product (CB-CAP) profiling is combined with determination of C4 gene copy number as biomarkers for lupus and/or pre-lupus diagnosis and monitoring.

公开(公告)号：US20230375544A1

公开(公告)日：2023-11-23

申请号：US18246792

申请日：2021-09-28

Applicant: Allegheny Singer Research Institute

Inventor： Joseph M. Ahearn ,  Chau-Ching Liu

IPC: G01N33/564 ,  C07K16/18

CPC classification number: G01N33/564 ,  C07K16/18 ,  G01N2333/4716 ,  G01N2800/104 ,  C07K2317/31

Abstract: This disclosure provides a novel method for detecting one or more cell fragment-bound complement activation products (CFB-CAPs) using a capillary flow system. The method eliminates the need for fresh, live cellular samples and detection by flow cytometric methods. The method as disclosed has a wide variety of applications, including diagnosing or monitoring lupus or pre-lupus and other diseases or disorders (e.g., autoimmune or inflammatory diseases or disorders).

公开(公告)号：US10067128B2

公开(公告)日：2018-09-04

申请号：US15223906

申请日：2016-07-29

Applicant: Allegheny-Singer Research Institute

Inventor： Joseph M. Ahearn ,  Chau-Ching Liu ,  Susan M. Manzi

IPC: G01N33/564 ,  G01N33/86 ,  G01N33/50 ,  G16H50/20 ,  G06F19/00

Abstract: Methods, systems, and kits useful for determining whether a subject is likely to benefit from therapy with an antibody are provided. In particular aspects, cell-bound complement activation products (CB-CAPs) associated with B lymphocytes may serve as diagnostic biomarkers.

公开(公告)号：US09495517B2

公开(公告)日：2016-11-15

申请号：US14820029

申请日：2015-08-06

Applicant: Allegheny-Singer Research Institute

Inventor： Joseph M. Ahearn ,  Chau-Ching Liu ,  Susan M. Manzi

IPC: C12Q1/68 ,  G01N33/53 ,  G06F19/00 ,  G01N33/49 ,  G01N33/564 ,  A61K39/395 ,  C12Q1/02

CPC classification number: G06F19/345 ,  C12Q1/6883 ,  C12Q2600/112 ,  G01N33/49 ,  G01N33/564 ,  G01N2800/24 ,  G06F19/00 ,  G16H50/20

Abstract: Cell-bound complement activation product (CB-CAP) profiling and scoring serve as diagnostic biomarkers for patients to determine whether a patient who has not met at least four American College of Rheumatology (or similar e.g. SLICC) criteria for a definite Lupus diagnosis should be classified as exhibiting a pre-existing condition that this document refers to as pre-Lupus.

Abstract translation: 细胞结合的补体活化产物（CB-CAP）分析和评分可作为患者的诊断性生物标志物，以确定是否至少有四名美国风湿病学会（或类似的例如SLICC）的患者是否符合确定的狼疮诊断标准 分类为本文件称为狼疮前的现有条件。

公开(公告)号：US09863946B2

公开(公告)日：2018-01-09

申请号：US15264516

申请日：2016-09-13

Applicant: ALLEGHENY-SINGER RESEARCH INSTITUTE

Inventor： Joseph M. Ahearn ,  Chau-Ching Liu ,  Susan M. Manzi

IPC: C12Q1/68 ,  G01N33/53 ,  G01N33/564 ,  G06F19/00 ,  G01N33/49

CPC classification number: G01N33/564 ,  C12Q1/6883 ,  C12Q2600/112 ,  G01N33/49 ,  G01N2333/4716 ,  G01N2800/104 ,  G01N2800/24 ,  G06F19/00 ,  G06F19/18 ,  G06F19/20 ,  G16H10/60 ,  G16H50/20 ,  G16H50/30

Abstract: Cell-bound complement activation product (CB-CAP) profiling and scoring serve as diagnostic biomarkers for patients to determine whether a patient who has not met at least four American College of Rheumatology (or similar e.g. SLICC) criteria for a definite Lupus diagnosis should be classified as exhibiting a pre-existing condition that this document refers to as pre-Lupus. This document also describes methods for determining whether a patient who has been determined to exhibit pre-Lupus has progressed to exhibiting definite Lupus.

公开(公告)号：US09709564B2

公开(公告)日：2017-07-18

申请号：US14821670

申请日：2015-08-07

Applicant: Allegheny-Singer Research Institute

Inventor： Joseph M. Ahearn ,  Chau-Ching Liu ,  Susan M. Manzi

IPC: G01N33/564 ,  G01N33/536 ,  G01N33/50 ,  G01N33/68

CPC classification number: G01N33/564 ,  G01N33/5047 ,  G01N33/505 ,  G01N33/5052 ,  G01N33/5055 ,  G01N33/536 ,  G01N33/6854 ,  G01N2333/7051 ,  G01N2333/70514 ,  G01N2333/70517 ,  G01N2800/104 ,  G01N2800/7095

Abstract: Provided are methods, systems, and kits for diagnosing or monitoring systemic lupus erythematosus in an individual. In particular aspects, in a blood sample containing white blood cells from the individual, autoantibodies deposited on or contacting with the surface of a T lymphocyte in the sample are quantitated.

公开(公告)号：US20230094382A1

公开(公告)日：2023-03-30

申请号：US17935767

申请日：2022-09-27

Applicant: Allegheny Singer Research Institute

Inventor： Joseph M. Ahearn ,  Chau-Ching Liu

IPC: G01N33/564 ,  C07K16/18

Abstract: This disclosure provides a novel method for detecting one or more cell-bound complement activation products (CB-CAPs) using a capillary tube agglutination/lattice formation test. The method as disclosed has a wide variety of applications, including diagnosing or monitoring lupus or pre-lupus and other diseases or disorders (e.g., autoimmune or inflammatory diseases or disorders).

公开(公告)号：US20170030905A1

公开(公告)日：2017-02-02

申请号：US15223906

申请日：2016-07-29

Applicant: Allegheny-Singer Research Institute

Inventor： Joseph M. Ahearn ,  Chau-Ching Liu ,  Susan M. Manzi

IPC: G01N33/564 ,  G06F19/00 ,  G01N33/50

CPC classification number: G01N33/564 ,  G01N33/5052 ,  G01N33/86 ,  G01N2333/4716 ,  G01N2800/52 ,  G06F19/00 ,  G16H50/20

Abstract: Methods, systems, and kits useful for determining whether a subject is likely to benefit from therapy with an antibody are provided. In particular aspects, cell-bound complement activation products (CB-CAPs) associated with B lymphocytes may serve as diagnostic biomarkers.

Abstract translation: 提供了可用于确定受试者是否可能受益于用抗体治疗的方法，系统和试剂盒。 在特定方面，与B淋巴细胞相关的细胞结合的补体活化产物（CB-CAP）可以用作诊断性生物标志物。

公开(公告)号：US20190302112A1

公开(公告)日：2019-10-03

申请号：US16303345

申请日：2017-05-24

Applicant: Allegheny Singer Research Institute ,  Research Institute At Nationwide Children's Hospital

Inventor： Joseph M. Ahearn ,  Chau-Ching Liu ,  Susan M. Manzi ,  C. Yung Yu

IPC: G01N33/564 ,  C12Q1/6883 ,  G16B20/10 ,  G16H15/00

Abstract: Cell-bound complement activation product (CB-CAP) profiling is combined with determination of C4 gene copy number as biomarkers for lupus and/or pre-lupus diagnosis and monitoring.

公开(公告)号：US20170067893A1

公开(公告)日：2017-03-09

申请号：US15264516

申请日：2016-09-13

Applicant: ALLEGHENY-SINGER RESEARCH INSTITUTE

Inventor： Joseph M. Ahearn ,  Chau-Ching Liu ,  Susan M. Manzi

IPC: G01N33/564 ,  G06F19/00

CPC classification number: G01N33/564 ,  C12Q1/6883 ,  C12Q2600/112 ,  G01N33/49 ,  G01N2333/4716 ,  G01N2800/104 ,  G01N2800/24 ,  G06F19/00 ,  G06F19/18 ,  G06F19/20 ,  G16H10/60 ,  G16H50/20 ,  G16H50/30

Abstract: Cell-bound complement activation product (CB-CAP) profiling and scoring serve as diagnostic biomarkers for patients to determine whether a patient who has not met at least four American College of Rheumatology (or similar e.g. SLICC) criteria for a definite Lupus diagnosis should be classified as exhibiting a pre-existing condition that this document refers to as pre-Lupus. This document also describes methods for determining whether a patient who has been determined to exhibit pre-Lupus has progressed to exhibiting definite Lupus.

Abstract translation: 细胞结合的补体活化产物（CB-CAP）分析和评分可作为患者的诊断性生物标志物，以确定是否至少有四名美国风湿病学会（或类似的例如SLICC）的患者是否符合确定的狼疮诊断标准 分类为本文件称为狼疮前的现有条件。 本文件还描述了确定是否已经确定展现预防狼疮的患者已经进展到出现明确的狼疮的方法。